Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476824 | 1.00 | ABCB1 (0.40) | ABCB1THRBALDH1A1TRPM8HTR6 | |
| Acetic Acid SCHEMBL6476822 | 0.80 | ABCB1 (0.46) | ABCB1MAPTENPP2 | |
| SCHEMBL6478016 | 0.74 | ABCB1 (0.48) | ABCB1ALDH1A1MAPT | |
| SCHEMBL6478007 | 0.74 | ABCB1 (0.48) | ABCB1ALDH1A1MAPT | |
| SCHEMBL6487252 | 0.71 | ABCB1 (0.43) | ABCB1ALDH1A1MAPT | |
| SCHEMBL6487256 | 0.71 | ABCB1 (0.43) | ABCB1ALDH1A1MAPT | |
| SCHEMBL6477752 | 0.70 | ABCB1 (0.47) | ABCB1ALDH1A1MAPT | |
| SCHEMBL6477755 | 0.70 | ABCB1 (0.47) | ABCB1ALDH1A1MAPT | |
| SCHEMBL6487165 | 0.69 | ABCB1 (0.45) | ABCB1ALDH1A1HTR6MAPT | |
| SCHEMBL6487159 | 0.69 | ABCB1 (0.45) | ABCB1ALDH1A1HTR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-20 | — | — | US | claimed |
| EP-1452525-A1 | AMIDE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452525-A1 | AMIDE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | TGFBR1, TGFBR2, TGFB1 | ABCB1 2911/4885THRB 455/4885ALDH1A1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.